You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 70 No. 1, July 1963 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (33)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Treatment of Herpetic Keratitis with 5-Iodo-2'-Deoxyuridine (IDU)

PETER R. LAIBSON, MD; THEODORE W. SERY, PhD; IRVING H. LEOPOLD, MD

Arch Ophthalmol. 1963;70(1):52-58.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Recently the topical application of an antimetabolite, 5-iodo-2'-deoxyuridine (IDU) has proved efficacious in the treatment of herpes simplex keratitis.1 Prior to this there was no known chemotherapeutic or antibiotic agent which was capable of inactivating or retarding the herpes simplex virus in vivo in man or animal.

Sery and Furgiuele2 had investigated over 150 compounds and found no significant antivirus activity in the treatment of herpes simplex infections in the rabbit cornea despite impressive virus neutralization properties of some in vitro. In past years numerous investigators have tested steroids, antibiotics, and enzymes in experimental animals and man. Antibiotics do not enhance the healing process after infection with herpes simplex, although they do protect against secondary infection.3 Anti-inflammatory steroids alter unfavorably the normal course of corneal herpes simplex infection when applied topically and/or used systemically.4,5 It has been suggested by clinical and experimental studies that the . . . [Full Text PDF of this Article]


Author Affiliations

Philadelphia

From the Research and Clinical Departments of the Wills Eye Hospital.


Footnotes

Submitted for publication Nov 1, 1962.

This investigation was supported by grant 2B-5076 from the National Institute of Neurological Diseases and Blindness, National Institutes of Health and by a grant from the Smith, Kline & French Laboratories.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1963 American Medical Association. All Rights Reserved.